NF-κB–driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance

Therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs, such as gefitinib or erlotinib) significantly prolongs survival time for patients with tumors harboring an activated mutation on EGFR; however, up to 40% of lung cancer patients exhibit acquired resistance to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Proceedings of the National Academy of Sciences - PNAS 2016-05, Vol.113 (18), p.E2526-E2535
Hauptverfasser:	Chiu, Ching-Feng, Chang, Yi-Wen, Kuo, Kuang-Tai, Shen, Yu-Shiuan, Liu, Chien-Ying, Yu, Yang-Hao, Cheng, Ching-Chia, Lee, Kang-Yun, Chen, Feng-Chi, Hsu, Min-Kung, Kuo, Tsang-Chih, Ma, Jui-Ti, Su, Jen-Liang
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Biological Sciences Dose-Response Relationship, Drug Down-Regulation - drug effects Drug Resistance, Neoplasm Female Forkhead Box Protein O3 - metabolism Humans Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Lung Neoplasms - pathology Male Middle Aged Mutation Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - metabolism Neoplastic Stem Cells - pathology NF-kappa B - metabolism PNAS Plus Protein Kinase Inhibitors - administration & dosage Quinazolines - administration & dosage Receptor, Epidermal Growth Factor - genetics Receptor, Epidermal Growth Factor - metabolism Treatment Outcome Tumor Cells, Cultured
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!